Management of metastatic castration-resistant prostate cancer after first-line docetaxel - Abstract

Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, England, UK.

 

Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.

Written by:
Harrington JA, Jones RJ.   Are you the author?

Reference: Eur J Cancer. 2011 Jun 7. Epub ahead of print.
doi: 10.1016/j.ejca.2011.04.036

PubMed Abstract
PMID: 21658937

UroToday.com Prostate Cancer Section

 

 

email news signup